<DOC>
	<DOC>NCT00687492</DOC>
	<brief_summary>The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.</brief_summary>
	<brief_title>Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>2 or more risk factors (according to NCEP ATP III guideline) Receiving lipidlowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks. Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site). Previous enrolment or randomisation of treatment in the present study. Participation in a clinical study during the last 90 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>NCEP ATP III guidelines</keyword>
	<keyword>survey</keyword>
</DOC>